TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis

University Hospital, Gentofte, Copenhagen60 enrolled

Overview

TNF alfa blockers are widely used for treatment of severe psoriasis. These biologics are well-tolerated with few side effects. Unfortunately not all patients respond adequately to treatment with tnf alfa blockers. Some do not respond at all while others respond initially but gradually lose effect despite increased dose and more frequent administration. The cause of treatment failure is largely unknown and it may be production of tnf-alfa neutralizing antibodies. This has been demonstrated in patients with rheumatoid arthritis and inflammatory bowel disease who lost response after treatment with tnf-alfa blockers.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Psoriasis

Interventions

subjects will receive either infliximab, adalimumab or etanercept

The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug. The study subjects will receive treatment with one drug only - 1. infliximab or 2. adalimumab or 3. etanercept The consulting dermatologist decides which drug to use according to official guidelines

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female * Age above 18 * Psoriasis * Indication for treatment with tnf alfa blocking drug * Written informed consent obtained Exclusion Criteria: * Severe psychiatric disorder * No indication for treatment with tnf-alfa blocking drug * Pregnancy * Breastfeeding * No written informed consent

Locations (2)

Copenhagen University Hospital Gentofte, Department of Skin and Allergies

Hellerup, Denmark

RECRUITING

Karolinska Institute, Department of Medicine

Stockholm, Sweden

RECRUITING